118 related articles for article (PubMed ID: 15113688)
1. Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms.
Qian J; Voorbach MJ; Huth JR; Coen ML; Zhang H; Ng SC; Comess KM; Petros AM; Rosenberg SH; Warrior U; Burns DJ
Anal Biochem; 2004 May; 328(2):131-8. PubMed ID: 15113688
[TBL] [Abstract][Full Text] [Related]
2. A new assay for the discovery of Bcl-XL inhibitors.
Pisoni C; Cimoli G; Resconi A; Losi D; Lorenzetti R; Parodi S; Carrano L
Farmaco; 2005; 60(11-12):938-43. PubMed ID: 16054143
[TBL] [Abstract][Full Text] [Related]
3. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions.
Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH
J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293
[TBL] [Abstract][Full Text] [Related]
4. A TR3/Nur77 peptide-based high-throughput fluorescence polarization screen for small molecule Bcl-B inhibitors.
Yip KW; Godoi PH; Zhai D; Garcia X; Cellitti JF; Cuddy M; Gerlic M; Chen Y; Satterthwait A; Vasile S; Sergienko E; Reed JC
J Biomol Screen; 2008 Aug; 13(7):665-73. PubMed ID: 18626112
[TBL] [Abstract][Full Text] [Related]
5. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies.
Petros AM; Nettesheim DG; Wang Y; Olejniczak ET; Meadows RP; Mack J; Swift K; Matayoshi ED; Zhang H; Thompson CB; Fesik SW
Protein Sci; 2000 Dec; 9(12):2528-34. PubMed ID: 11206074
[TBL] [Abstract][Full Text] [Related]
6. Deciphering the antitumoral activity of quinacrine: Binding to and inhibition of Bcl-xL.
Orzáez M; Mondragón L; García-Jareño A; Mosulén S; Pineda-Lucena A; Pérez-Payá E
Bioorg Med Chem Lett; 2009 Mar; 19(6):1592-5. PubMed ID: 19237284
[TBL] [Abstract][Full Text] [Related]
7. Distinct domains of Bcl-XL are involved in Bax and Bad antagonism and in apoptosis inhibition.
Zhou H; Hou Q; Chai Y; Hsu YT
Exp Cell Res; 2005 Oct; 309(2):316-28. PubMed ID: 16061221
[TBL] [Abstract][Full Text] [Related]
8. Genomic profiling of acquired resistance to apoptosis in cells derived from human atherosclerotic lesions: potential role of STATs, cyclinD1, BAD, and Bcl-XL.
Gagarin D; Yang Z; Butler J; Wimmer M; Du B; Cahan P; McCaffrey TA
J Mol Cell Cardiol; 2005 Sep; 39(3):453-65. PubMed ID: 16005468
[TBL] [Abstract][Full Text] [Related]
9. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft.
Zhang YH; Bhunia A; Wan KF; Lee MC; Chan SL; Yu VC; Mok YK
J Mol Biol; 2006 Dec; 364(3):536-49. PubMed ID: 17011577
[TBL] [Abstract][Full Text] [Related]
10. Robust lanthanide-based assays for the detection of anti-apoptotic Bcl-2-family protein antagonists.
Rega MF; Reed JC; Pellecchia M
Bioorg Chem; 2007 Apr; 35(2):113-20. PubMed ID: 16996562
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
[TBL] [Abstract][Full Text] [Related]
12. Development of a high-throughput fluorescence polarization assay for Bcl-x(L).
Zhang H; Nimmer P; Rosenberg SH; Ng SC; Joseph M
Anal Biochem; 2002 Aug; 307(1):70-5. PubMed ID: 12137781
[TBL] [Abstract][Full Text] [Related]
13. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures.
Annis DA; Nazef N; Chuang CC; Scott MP; Nash HM
J Am Chem Soc; 2004 Dec; 126(47):15495-503. PubMed ID: 15563178
[TBL] [Abstract][Full Text] [Related]
14. Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL.
Yin H; Lee GI; Sedey KA; Kutzki O; Park HS; Orner BP; Ernst JT; Wang HG; Sebti SM; Hamilton AD
J Am Chem Soc; 2005 Jul; 127(29):10191-6. PubMed ID: 16028929
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma.
Shiau CW; Yang CC; Kulp SK; Chen KF; Chen CS; Huang JW; Chen CS
Cancer Res; 2005 Feb; 65(4):1561-9. PubMed ID: 15735046
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship studies of phenanthridine-based Bcl-XL inhibitors.
Bernardo PH; Wan KF; Sivaraman T; Xu J; Moore FK; Hung AW; Mok HY; Yu VC; Chai CL
J Med Chem; 2008 Nov; 51(21):6699-710. PubMed ID: 18925736
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis.
Petros AM; Dinges J; Augeri DJ; Baumeister SA; Betebenner DA; Bures MG; Elmore SW; Hajduk PJ; Joseph MK; Landis SK; Nettesheim DG; Rosenberg SH; Shen W; Thomas S; Wang X; Zanze I; Zhang H; Fesik SW
J Med Chem; 2006 Jan; 49(2):656-63. PubMed ID: 16420051
[TBL] [Abstract][Full Text] [Related]
18. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
19. Membrane-insertion fragments of Bcl-xL, Bax, and Bid.
García-Sáez AJ; Mingarro I; Pérez-Payá E; Salgado J
Biochemistry; 2004 Aug; 43(34):10930-43. PubMed ID: 15323553
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
Doshi JM; Tian D; Xing C
J Med Chem; 2006 Dec; 49(26):7731-9. PubMed ID: 17181155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
